VSSPY yields 13.95% · PFE yields 6.20%● Live data
📍 VSSPY pulled ahead of the other in Year 1
Combined, VSSPY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VSSPY + PFE for your $10,000?
Valid Soluções S.A. provides security printing services for payment and mobile solutions, identity solutions, digital marketing, and digital certification worldwide. It operates through Means of Payment, Identification, and Mobile segments. The Means of Payment segment offers integrated products and solutions, such as chip and magnetic stripe cards, gift cards, check printing, invoices, and bank statements, as well as solutions in radio frequency identification, contactless cards, and mobile payments. The Identification segment provides physical and electronic solutions, such as data collection, storage and management, security prints, recognition, and digital printing. Its solutions are used in the generation of computerized systems for the administration of databases, collection of biometric data, printing and customization of official identification documents, solutions for smart cities, and traceable stamps. The Mobile segment offers services of issuing statements and technologies for use in cell phones, and digital mobility, such as NFC, TSM, and HCE solutions for mobile service providers. It also develops technologies for use in cell phones, such as recharge and payment and production of cards intended for telecommunications. The company serves state governments and government agencies, large financial institutions, telecommunications companies, retailers, agriculture cooperatives, and self-employed professionals. The company was formerly known as Valid Soluções e Serviços de Segurança em Meios de Pagamento e Identificação S.A. and changed its name to Valid Soluções S.A. in August 2018. Valid Soluções S.A. was founded in 1957 and is headquartered in Rio de Janeiro, Brazil.
Full VSSPY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.